Cystatin c: a Biomarker of AKI in Aneurysmal Subarachnoid Haemorrhage Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

52 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-30

Study Completion Date

2025-01-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to assess cystatin c as a predictive biomarker of early acute kidney injury in aneurysmal subarachnoid hemorrhage patients. The main question it aims to answer is:

\- Does cystatin c biomarker can predict early acute kidney injury in aneurysmal subarachnoid hemorrhage patients?

Participants will be grouped into Aki and Non-Aki groups based on RIFLE criteria and Cystatin c biomarker will be tested to answer the study question.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Role of NGAL and Cystatin C in Prediction of Acute Kidney Injury Covid-19 Infection

NCT04603664

Biochemical Markers ,NGAL,Cystatin c, Acute Kidneyinjury, Covid 19

COMPLETED

Serum Cystatin C for Early Detection of Acute Kidney Injury After Primary Percutaneous Coronary Intervention

NCT06459362

Acute Kidney Injury

NOT_YET_RECRUITING

Cystatin and Early AKI Detection Contrast Induced Acute Kidney Injury

NCT07197957

Acute Kidney Injury

RECRUITING

Serum Cysteine Rich Protein 61 and Cystatin C for Early Detection of Acute Kidney Injury in Patients With Heart Diseases

NCT05242705

Acute Kidney Injury

UNKNOWN

Acute Kidney Injury in Newborns With Perinatal Asphyxia

NCT03617055

Acute Kidney Injury

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Kidney Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aki group

Cystatin c biomarker will be assessed to predict occurrence of early acute kidney injury

cystatin c

Intervention Type DIAGNOSTIC_TEST

a biomarker to assess renal function

Non-Aki group

participants in this group will not develop acute kidney injury throughout the study duration

cystatin c

Intervention Type DIAGNOSTIC_TEST

a biomarker to assess renal function

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cystatin c

a biomarker to assess renal function

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient admission to hospital within 48 hours of subarachnoid haemorrhage onset.
* Subarachnoid haemorrhage caused by intracranial aneurysm rupture and is confirmed via computed tomography angiography (CTA).
* Medical treatment, microsurgical clipping, or interventional endovascular treatment of aneurysm is performed within 48 hours of subarachnoid haemorrhage onset.

Exclusion Criteria

* Prior onset of subarachnoid haemorrhage or other neurological diseases such as ischemic stroke, hemorrhagic stroke, or severe head trauma.
* Systemic diseases, such as chronic liver diseases, chronic lung diseases, chronic heart failure, thyroid diseases and cancer.
* Renal impairment at time of admission (creatinine-based eGFR less than 60 ml/min per 1.73 m2 body surface area).
* Patients who are hemodynamically unstable at time of admission.
* Mortality within 10 days after admission (duration of study).

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes